Biomarker-driven trials may improve personalized treatment for lung cancer
Innovative clinical trials that assign patients to treatment arms based on tumor biomarkers could lead to increased treatment options for patients with lung cancer.
On June 16, SWOG (formerly the Southwest Oncology Group), in cooperation with the National Cancer Institute’s (NCI) National Clinical Trials Network, activated the Lung-MAP trial, a large biomarker-driven clinical trial of targeted therapies for squamous cell lung cancer...
